<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943904</url>
  </required_header>
  <id_info>
    <org_study_id>2009-6799</org_study_id>
    <nct_id>NCT00943904</nct_id>
  </id_info>
  <brief_title>Comparison of Motor and Sensory Response With Interstim Stimulation</brief_title>
  <official_title>Comparison of Motor and Sensory Response With Interstim Stimulation for Overactive Bladder and Urgency-Frequency Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sacral nerve stimulation (SNS) implantation is a minimally invasive procedure which has&#xD;
      current FDA approval for urinary urge incontinence, urgency-frequency syndrome and&#xD;
      non-obstructive urinary retention, and has been available in the United States since 1997.&#xD;
      The SNS delivers non-painful, mild electrical pulses to the sacral nerves to modulate the&#xD;
      reflexes that influence the bladder, sphincter, and pelvic floor to improve or restore normal&#xD;
      voiding function. While SNS has been shown to have efficacy for the aforementioned&#xD;
      conditions, the exact mechanism of action is unknown, but it is believed to work primarily&#xD;
      through the somatic afferent system in promoting inhibitory reflex pathways to facilitate&#xD;
      urine storage. The degree of stimulation is thought to be at a level that only evokes a&#xD;
      sensory and not a motor response; however this has not been tested.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SNS involves a two-stage procedure. The initial phase is considered the test stimulation&#xD;
      period where the patient is allowed to evaluate whether or not the therapy is effective in&#xD;
      controlling her symptoms. There are two techniques that exist in performing the test&#xD;
      stimulation. The first is an office-based procedure termed the percutaneous nerve evaluation&#xD;
      (PNE). This involves placing a temporary electrode wire through the S3 sacral foramen under&#xD;
      local anesthesia. The wire is secured with tape and connected to an external generator the&#xD;
      patient wears for a trial period of 3-7 days. If patients have at least 50% improvement in&#xD;
      their symptoms during the test phase, they are candidates for chronic implant of the lead and&#xD;
      implantable pulse generator (IPG). The advantage of the PNE is that it is an incision free&#xD;
      procedure performed in the office utilizing local anesthesia, and does not require&#xD;
      hospitalization. The disadvantage comes from the fact that the wire is not securely anchored&#xD;
      in place, and has the propensity to migrate away from the nerve with physical activity. The&#xD;
      second alternative is known as a staged implant. This is typically performed as an outpatient&#xD;
      procedure using local anesthesia, intravenous sedation, and intra-operative fluoroscopy. This&#xD;
      procedure involves placement of the chronic quadripolar lead wire adjacent to a sacral nerve&#xD;
      root (typically S3). The lead is self-anchoring and therefore reduces the potential for&#xD;
      migration. The patient goes through a test phase that can last from 7-21 days. The advantage&#xD;
      of this technique is that it allows for a longer trial period with minimal risk of lead&#xD;
      migration. The chronic wire also has 4 electrodes that can each be trialed as the active&#xD;
      electrode to achieve optimal improvement in patients' symptoms. In addition, during the 2nd&#xD;
      stage, or final implant the previously placed tined-lead remains in place and is simply&#xD;
      connected to the IPG. This eliminates the chance of variable lead placement from the test and&#xD;
      implantation phases. The disadvantage of the staged implant is that it requires two visits to&#xD;
      the operating room and may be more costly to the health care system. However, in a&#xD;
      prospective study comparing the PNE to the staged implant, there was a significantly higher&#xD;
      rate of conversion to implant with the staged procedure vs. the PNE (88% vs.46%). In&#xD;
      addition, infection rates are not higher with the staged implant when compared to the PNE.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Symptoms With Improvement of Leaks Reported</measure>
    <time_frame>6 months following enrollment</time_frame>
    <description>Percent change in improvement of symptoms after reprogramming in terms of number of leaks reported. Nocturia refers to leaks that happened while asleep. Incontinence refers to both stress and urge leaks. Urgency refers to only urge leaks. Positive values represent more improvement of symptoms and therefore less leaks. Negative values represent less improvement and therefore more leaks.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Urgency-Frequency</condition>
  <arm_group>
    <arm_group_label>Interstim stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who receive the interstim implant in order to evaluate effectiveness of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Interstim implant for SNS</intervention_name>
    <description>stimulates third sacral nerve root</description>
    <arm_group_label>Interstim stimulation</arm_group_label>
    <other_name>Sacral nerve Stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  You are eligible to participate in this study if:&#xD;
&#xD;
               -  you are at least 18 years of age or older&#xD;
&#xD;
               -  you have the capacity to give informed consent&#xD;
&#xD;
               -  you are currently implanted with a functioning Interstim device for the treatment&#xD;
                  of urge urinary leakage or overactive bladder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  You are not eligible to participate in this study if:&#xD;
&#xD;
               -  you do not meet the inclusion criteria and/or are not able to fully empty your&#xD;
                  bladder&#xD;
&#xD;
               -  you have a history of an underlying neurologic disorder&#xD;
&#xD;
               -  you are currently pregnant, or have an active urinary tract or vaginal infection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Noblett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCI Women's Healthcare</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <results_first_submitted>May 25, 2017</results_first_submitted>
  <results_first_submitted_qc>September 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2021</results_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Karen Noblett</investigator_full_name>
    <investigator_title>Division Director</investigator_title>
  </responsible_party>
  <keyword>urinary leakage associated with urinary urgency</keyword>
  <keyword>unable to fully empty bladder</keyword>
  <keyword>Comparison: Motor&amp;Sensory Response to Interstim Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Interstim Stimulation</title>
          <description>Patients who receive the interstim implant in order to evaluate effectiveness of treatment&#xD;
Interstim implant for SNS: stimulates third sacral nerve root</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Interstim Stimulation</title>
          <description>Patients who receive the interstim implant in order to evaluate effectiveness of treatment&#xD;
Interstim implant for SNS: stimulates third sacral nerve root</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Symptoms With Improvement of Leaks Reported</title>
        <description>Percent change in improvement of symptoms after reprogramming in terms of number of leaks reported. Nocturia refers to leaks that happened while asleep. Incontinence refers to both stress and urge leaks. Urgency refers to only urge leaks. Positive values represent more improvement of symptoms and therefore less leaks. Negative values represent less improvement and therefore more leaks.</description>
        <time_frame>6 months following enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Interstim Stimulation</title>
            <description>Patients who receive the interstim implant in order to evaluate effectiveness of treatment&#xD;
Interstim implant for SNS: stimulates third sacral nerve root</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Symptoms With Improvement of Leaks Reported</title>
          <description>Percent change in improvement of symptoms after reprogramming in terms of number of leaks reported. Nocturia refers to leaks that happened while asleep. Incontinence refers to both stress and urge leaks. Urgency refers to only urge leaks. Positive values represent more improvement of symptoms and therefore less leaks. Negative values represent less improvement and therefore more leaks.</description>
          <units>Percent change in leaks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nocturia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incontinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urgency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Interstim Stimulation</title>
          <description>Patients who receive the interstim implant in order to evaluate effectiveness of treatment&#xD;
Interstim implant for SNS: stimulates third sacral nerve root</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Karen Noblett</name_or_title>
      <organization>University of California, Riverside</organization>
      <phone>(951) 827-7581</phone>
      <email>karen.noblett@ucr.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

